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Effects of Cholecystokinin in the Supraoptic Nucleus and Paraventricular
Nucleus are Negatively Modulated by Leptin in 24-h Fasted Lean Male
Rats
C. Caquineau, A. J. Douglas and G. Leng
Centre for Integrative Physiology, University of Edinburgh, Edinburgh, UK.
Cholecystokinin (CCK) is an important satiety factor that regulates
how much food is consumed during a meal. Released from the gut
during eating, CCK acts via CCK-A receptors that are located on the
nerve endings of gastric vagal afferents projecting to the nucleus
tractus solitarii (NTS) in the caudal brainstem. In rats and mice,
systemic injections of CCK induce expression of Fos (the protein
product of the immediate-early gene c-fos) in neurones in the NTS,
and also in several hypothalamic nuclei that receive projections
from the NTS, including both parvocellular and magnocellular oxy-
tocin neurones in the paraventricular nucleus (PVN) and supraoptic
nucleus (SON) (1). At least some of the parvocellular oxytocin
neurones of the PVN that are activated by CCK project back to the
NTS, where there is dense expression of oxytocin receptors (2).
There, they activate a descending vagal efferent pathway that regu-
lates the passage of food through the gut (3). As a result of the
activation of magnocellular oxytocin neurones, CCK stimulates
magnocellular oxytocin secretion from the posterior pituitary into
the systemic circulation (4). Peripherally-administered oxytocin
stimulates sodium excretion (natriuresis) by a combination of direct
actions at the kidney and indirect actions of atrial natriuretic pep-
tides from the heart, It has therefore been proposed that oxytocin
secreted in response to CCK reﬂects a reﬂex pathway that
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Cholecystokinin (CCK) and leptin are two important satiety factors that are considered to act in
synergy to reduce meal size. Peripheral injection of CCK activates neurones in several hypotha-
lamic nuclei, including the supraoptic (SON) and paraventricular (PVN) nuclei and neurones in
the brainstem of fed rats. We investigated whether peripheral leptin would modulate the effects
of CCK on neuronal activity in the hypothalamus and brainstem of fasted rats by investigating
Fos expression in the PVN, SON, arcuate nucleus, ventromedial hypothalamus (VMH), dorsomedi-
al hypothalamus (DMH), area postrema (AP) and the nucleus tractus solitarii (NTS). Male rats,
fasted for 24 h, received either one i.p. injection of vehicle, leptin or CCK-8 alone, or received
one injection of vehicle or leptin before an i.p. injection of CCK-8. We found that CCK increased
Fos expression in the PVN and SON as well as in the NTS and AP, but had no effect on Fos
expression in the arcuate nucleus, VMH or DMH compared to vehicle. Leptin injected alone sig-
niﬁcantly increased Fos expression in the arcuate nucleus but had no effect on Fos expression
in the VMH, DMH, SON, PVN, AP or NTS compared to vehicle. Fos expression was signiﬁcantly
increased in the AP in rats injected with both leptin and CCK compared to rats injected with
vehicle and CCK. Unexpectedly, there was signiﬁcantly less Fos expression in the PVN and SON
of fasted rats injected with leptin and CCK than in rats injected with vehicle and CCK, suggest-
ing that leptin attenuated CCK-induced Fos expression in the SON and PVN. However, Fos
expression in the NTS was similar in fasted rats injected with vehicle and CCK or with leptin
and CCK. Taken together, these results suggest that leptin dampens the effects of CCK on Fos
expression in the SON and PVN, independently from NTS pathways, and this may reﬂect a direct
action on magnocellular neurones.
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From Molecular to Translational Neurobiologystimulates natriuresis to compensate for the sodium intake accom-
panying feeding (5). Oxytocin is also released in the hypothalamus
from both parvocellular and magnocellular neurones to inhibit food
intake by acting on important satiety centres such as the ventro-
medial nucleus of the hypothalamus (VMH), which expresses oxyto-
cin receptors in abundance (6).
The satiety-inducing effects of CCK appear to be modulated by
prevailing concentrations of leptin, a hormone released from adi-
pose tissue that is an important long-term regulator of food
intake (7–9). Plasma concentrations of leptin increase with feeding
and decrease with fasting and, in rats fasted for 48 h, systemic
injections of CCK are less potent at reducing food intake than in
fed rats, although this is reversed by leptin administration (8).
Leptin receptors are expressed in afferent vagal neurones in the
NTS (10–12) and some reports indicate that leptin receptors are
particularly abundant in the SON and PVN (13–15). The actions of
leptin in the brain are classically mediated by a Janus kinase-sig-
nal transducer and activator of transcription (STAT) pathway,
resulting in the regulation of target gene expression (16–18).
A recent microarray study of the PVN reported that, in fasted
mice, in which oxytocin is, as for rats, anorexigenic, oxytocin
mRNA expression is reduced, and that this effect of fasting is
reversed after systemic administration of leptin, suggesting that
leptin may have an important action in modulating the rate of
synthesis of oxytocin (19).
In the present study, we tested the hypothesis that leptin poten-
tiates the responsiveness of supraoptic and paraventricular neuro-
nes to CCK. We ﬁrst studied CCK-induced expression of Fos protein
in fasted rats, which have low circulating concentrations of leptin,
and then studied the effects of pre-treatment with leptin on the
CCK response.
Materials and methods
All animal experiments were performed under project and personal licenses
awarded by the UK Home Ofﬁce, and in accordance with Home Ofﬁce
guidelines.
Animals
Adult male Sprague-Dawley rats were housed individually under a 12 : 12 h
light⁄dark cycle, at an average room temperature of 22  C with food and
water available ad lib. Twenty-four hours before beginning experiments, food
was removed for all rats. Rats had free access to drinking water throughout.
Intraperitoneal injections
Experiments began at 3 h after lights on. In a ﬁrst experiment, 24-h fasted
rats (250–270 g body weight) were injected i.p. with either 1 ml of vehicle
(0.9% saline), leptin (recombinant rat leptin; PeproTech EC Ltd, London, UK;
50 lg⁄rat), or CCK-8 [Tocris, Bristol, UK; 15 lg⁄rat; as described previously
(20)]. In a second experiment, 24-h fasted rats (300–320 g body weight)
were injected i.p. with 1 ml of vehicle or leptin (50 lg⁄rat) followed by
CCK-8 (15 lg⁄rat) 15 min later. Doses of leptin in the range 0.1–1 mg⁄kg
have previously been shown to be effective in inducing Fos expression and
nuclear pSTAT3 in the VMH and in the arcuate nucleus (18, 21, 22). Leptin
has a half-life in the circulation of approximately 9 min in rats (23), and
in vivo studies of the electrophysiological effects of leptin (in the PVN and
on midbrain dopamine neurones) have indicated maximal effects at approxi-
mately 20 min after injection (24, 25). Thus, we administered leptin by a
physiological (systemic) route, at a dose in the physiological range, and
timed the CCK injection to coincide with the expected peak of neuronal
responsiveness to systemically applied leptin.
At 90 min after the ﬁrst injection, rats were killed with an overdose of
sodium pentobarbitone (1 ml i.p.) and transcardially perfused with heparin-
ised 0.9% saline, followed by 4% paraformaldehyde in 0.1 M phosphate-buf-
fered saline. The brains were removed, post-ﬁxed overnight, cryoprotected in
30% sucrose, and stored at )20  C before processing for immunocyto-
chemistry.
Immunocytochemistry
Coronal brain sections (44 lm) were cut on a freezing microtome. Free-
ﬂoating sections were immunostained using a polyclonal antibody raised in
rabbit against Fos, the N-terminal amino-acids 4–17 of the protein product
of human c-fos (Ab-2; Calbiochem–Novabiochem, Nottingham, UK) diluted
at 1 : 1000 in a pre-incubation phosphate buffer containing 1% normal
goat serum. NTS noradrenergic neurones are known to be the source of the
afferent pathway to the PVN and SON through which CCK exerts its effects
(26). To identify any potential modulation in the neuronal activity of the
NTS noradrenergic neurones, some brainstem sections were also double im-
munostained for Fos and tyrosine hydroxylase (TH; the rate limiting enzyme
in noradrenaline synthesis) using a monoclonal anti-TH antibody raised in
mouse (Chemicon⁄Millipore, Watford, UK) at 1 : 1000 in a pre-incubation
phosphate buffer containing 1% normal goat serum. To detect pSTAT3
expression, which reﬂects activation of the leptin receptor, hypothalamic
sections were pre-incubated in tris citrate buffer (pH 8.5) at 80  C, and
incubated overnight with a rabbit anti-pSTAT3 (Tyr 705) antibody (Cell Sig-
naling Technology, Danvers, MA, USA) at 1 : 1000 in a phosphate buffer
containing 5% normal horse serum. For immunostaining, antibody-antigen
complexes were visualised using ABC methods with a Vector stain elite kit
(Vector Laboratories, Bucks, UK) with nickel-intensiﬁed diaminobenzidine
(Ni-DAB; for Fos, black nuclear label) or with DAB only [for TH or pSTAT3,
brown cytoplasmic or nuclear label respectively as descrined previously (27)].
Immunoreactivity was analysed in blind-coded sections using a Leica micro-
scope (Leica Microsystems, Wetzlar, Germany). Fos-positive neuronal nuclei
were counted in the SON at the level of maximal cross-sectional area, in
the PVN (1.80 mm posterior to bregma by reference to (28), in the arcuate
nucleus (from 2.30–3.30 mm posterior to bregma) in the dorsomedial hypo-
thalamus (from 2.56–3.14 mm posterior to bregma) and in the VMH (from
2.30–2.80 mm posterior to bregma) as well as in the NTS (from 13.30–
13.80 mm posterior to bregma) and in the area postrema (from 13.68–
13.80 mm posterior to bregma). In the PVN, magnocellular and parvocellular
regions were counted separately by comparing sections with brain atlas sec-
tions (28). At the level counted, the parvocellular PVN includes the dorsal
cap and ventromedial subdivisions. At least three sections per rat were
counted for each area.
Statistical analysis
Fos and pSTAT3 expressions in different brain areas were compared
between groups using a t-test or Mann–Whitney rank sum test where the
experimental design involved comparing just two treatments. For the
experiment involving more than two groups, one-way ANOVA or ANOVA on
ranks were performed followed by pairwise testing using parametric tests
(Newman–Keuls) or their nonparametric equivalents (Dunn’s Method) where
normality assumptions were violated. P < 0.05 was considered statistically
signiﬁcant.
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Effects of i.p. CCK or leptin on Fos expression in the
hypothalamus and caudal brainstem
To establish the effects of CCK or leptin alone on Fos expression in
fasted rats, rats without access to food for 24 h were injected i.p.
with either vehicle, leptin or CCK. As for fed rats, i.p injections of
CCK in fasted rats signiﬁcantly increased Fos expression in the SON,
and in the PVN compared to vehicle-injected rats (Fig. 1; P < 0.001)
in both magnocellular and parvocellular regions. CCK also induced
a modest but signiﬁcant increase in Fos expression in the arcuate
nucleus, although there was no signiﬁcant effect on Fos expression
in the VMH or DMH. CCK signiﬁcantly increased Fos expression in
the area postrema and in the NTS, including in TH-containing neu-
rones; 20% of TH-containing neurones in the NTS expressed Fos in
rats treated with CCK compared to only 4% of TH cells in vehicle-
treated rats, n = 6 per group, Mann–Whitney rank sum test;
P = 0.015; result not shown).
Consistent with previous studies (29), i.p. injections of leptin
alone increased Fos expression in the arcuate nucleus of fasted
rats, but had no signiﬁcant effect on Fos expression in the SON,
PVN, VMN, DMH, area postrema or in the NTS (Fig. 1). Although
leptin apparently inhibited Fos expression in both the SON and in
the PVN, these effects were not statistically signiﬁcant (P = 0.300).
Effects of i.p. leptin, CCK and leptin + CCK on pSTAT3
expression in fasted rats
Classically, the actions of leptin in the brain commonly result in
phosphorylation of STAT3, which is then translocated to the cell
nucleus. To conﬁrm that the dose of leptin used was physiologically
active, we therefore measured nuclear pSTAT3 expression in the
hypothalamus on selected sections from both experiments. In lep-
tin-injected rats, there was signiﬁcantly more nuclear pSTAT3
expression in the arcuate nucleus and in the VMH than in vehicle-
injected rats (Fig. 2A, D), although we saw no evidence of nuclear
pSTAT3 expression in the SON, PVN or DMH (data not shown).
CCK alone had no signiﬁcant effect on pSTAT3 expression in any
region of the hypothalamus studied, including the arcuate nucleus
and VMH (Fig. 2B, D), and had no effect on responsiveness to leptin
because there was no signiﬁcant difference in the pSTAT3 expres-
sion seen in the VMH and in the arcuate nucleus between rats
injected with leptin and rats injected with leptin and CCK
(Fig. 2C, D).
Effects of i.p. leptin on CCK-induced Fos expression in
fasted rats
To test the prediction that the responses to CCK in fasted rats
would be enhanced by pretreatment with leptin, 24-h fasted rats
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Fig. 1. Effects of i.p. leptin or i.p. cholecystokinin (CCK) on Fos expression in the hypothalamus, in the area postrema and in the nucleus tractus solitarii (NTS)
of fasted rats. Mean Fos-positive cells⁄section  SEM. The number of rats per group is shown in parentheses. *P < 0.05 or ***P < 0.01 versus vehicle-treated
group; ###P < 0.01 versus leptin-treated group (one-way ANOVA followed by Student–Newmann–Keuls method or ANOVA on ranks followed by Dunn’s method).
AP, Area postrema; SON, supraoptic nucleus; PVN, paraventricular nucleus; ARC, arcuate nucleus; VMH, ventromedial hypothalamus; DMH, dorsomedial hypo-
thalamus.
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with i.p. CCK. Fos expression was then analysed in the hypothala-
mus and caudal brainstem. There was no signiﬁcant difference in
Fos expression between rats treated with leptin and CCK and rats
treated with vehicle and CCK in either the arcuate nucleus or the
NTS (Figs 3 and 4) and, within the NTS, the proportion of TH neuro-
nes that expressed Fos was also similar in both groups (data not
shown). By contrast, Fos expression in both the SON and in the
magnocellular PVN was unexpectedly but signiﬁcantly reduced in
rats injected with leptin and CCK compared to rats injected with
vehicle and CCK (Figs 3 and 4). Fos expression in the area postrema
was signiﬁcantly increased in rats treated with both leptin and CCK
compared to vehicle and CCK (Figs 3 and 4; P < 0.001). There was
no signiﬁcant difference in Fos expression in the parvocellular PVN
(counts from dorsal and ventromedial subdivisions combined).
Discussion
In the present study, we tested the hypothesis that leptin and CCK
interact synergistically in signalling to the hypothalamus. In fasted
rats, with low circulating levels of leptin, we evaluated CCK
responses by quantifying Fos expression in discrete areas of the
hypothalamus. We then investigated the effects of pretreating
fasted rats with leptin on the measured responses to CCK, using a
dose that was effective in increasing pSTAT3 expression in the arcu-
ate nucleus and VMH.
We found that leptin potentiated CCK-induced Fos expression in
the area postrema, a circumventricular organ that lies outside the
blood–brain barrier, and which is involved in regulation of energy
intake. The area postrema contains neurones that are directly
excited by circulating CCK (30); thus, the Fos expression in this area
that is induced by CCK is therefore likely, in part at least, to reﬂect
a local action, but may also involve indirect actions via connections
between the area postrema and the adjacent NTS (31).
Previous studies (32, 33) have reported that i.c.v. administration
of leptin potentiates CCK-induced Fos expression in both the NTS
and the area postrema. In the present study, we saw that systemi-
cally applied leptin potentiated CCK responses only in the area pos-
trema with no effect in the NTS. This suggests that leptin and CCK
interact directly at the level of the area postrema, although it is
not clear at present whether leptin receptors are also expressed in
the area postrema (31). Because no potentiation was seen in the
NTS (the source of the major direct projection to the hypothalamus
from this region of the caudal brainstem), it is unlikely that leptin
potentiation of CCK responses in the area postrema will affect
hypothalamic networks, although it might inﬂuence efferent regula-
tion of the gastric system (31). The existence of leptin receptors in
the NTS remains uncertain because of conﬂicting observations (12,
34, 35). By contrast to previous studies (32, 33, 36, 37), we saw no
effect of leptin on Fos expression in the NTS, suggesting that, at
this dose and by this route, leptin has no effect on the NTS; differ-
ences between the present results and those of previous studies
(32, 33) probably reﬂect differences in the doses used and the
routes of administration.
The present study was focussed on interactions expressed in the
response of neurones in the SON and PVN. We used a dose of CCK
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Fig. 2. Effects of i.p. leptin, i.p. cholecystokinin (CCK) and i.p. leptin and CCK on pSTAT3 expression in the arcuate nucleus and in the ventromedial hypothala-
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cal activity of magnocellular neurones, its effects on neurohypo-
physial hormone secretion, and its effects on Fos expression
throughout the rat brain (20, 38, 39). We used leptin by a physio-
logical route of administration, at a dose that was adequate to
induce pSTAT3 expression in the arcuate nucleus and VMH
[conﬁrming previous reports in fed mice (16)]. Previous studies have
reported that peripherally-administered leptin also induces Fos
expression in the VMH of fed rats (21), but we found no response
in fasted rats in the present study.
Unexpectedly, we found that leptin does not potentiate but
dampens the effects of CCK on Fos expression in the magnocellular
neurones of the SON and PVN. It is likely that this reﬂects a direct
action of leptin on these neurones because it has been reported that
they express a high density of leptin receptors (13), and because we
saw no similar change in the NTS, the origin of the afferent pathway
that mediates the activation of oxytocin neurones by CCK. Because
Fos expression is usually interpreted as a marker of neuronal excita-
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Fig. 3. Photomicrograph illustrating Fos immunocytochemistry in the supra-
optic nucleus (SON) (A), in the paraventricular nucleus (PVN) (B), in the
nucleus tractus solitarii (NTS) and in the area postrema (C) of fasted rats
after i.p. leptin and cholecystokinin injections. Black arrow: Fos-positive neu-
rone. Scale bar = 100 lm. pmPVN, Magnocellular divisions of the paraven-
tricular nucleus; parvoPVN, parvocellular subdivisions of the paraventricular
nucleus; OC, optic chiasm; 3V, third ventricle; AP, area postrema; CC, central
canal; 4V, fourth ventricle.
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cell activity in the SON and PVN, suppressing the responsiveness of
these neurones to CCK-stimulated pathways. However, Fos expres-
sion does not consistently parallel changes in electrical activity (40).
In oxytocin neurones of the SON, Fos expression in response to CCK
or in response to hypertonic saline injection parallels the increased
electrical activity in fed rats (20), although i.c.v. administration of
a-MSH induces Fos expression in oxytocin neurones yet reduces
their electrical activity (41). In anaesthetised rats, the electrical activ-
ity of both oxytocin and vasopressin neurones is modestly but
consistently activated in response to injections of leptin (42). Thus,
although the direct actions of leptin on magnocellular neurones
appear to result in a suppression of Fos expression, they do not
result in a simultaneous suppression of electrical activity.
We saw no induction of pSTAT3 expression in the SON. Consis-
tent with this, although i.c.v. leptin strongly induces nuclear STAT3
immunoreactivity in the arcuate nucleus, VMH and DMH, it does
not do so in the SON (43), whereas nuclear STAT3 immunoreactivity
in this nucleus can be induced by interleukin-6 (44). It appears that,
although supraoptic neurones express leptin receptors in abun-
dance, systematically applied leptin does not reach the SON or the
receptors in the SON do not signal via STAT3. It is possible, how-
ever, that they may signal via nuclear translocation of STAT5; in a
study by Mutze et al. (45), systemic administration of a high dose
of leptin induced intense nuclear STAT5 staining in the SON as well
as the arcuate nucleus, but not in the VMH or DMH.
In summary, leptin signals in the brain involve distinct signalling
pathways in different neuronal populations. In oxytocin neurones,
leptin receptors may signal via STAT5 rather than via STAT3. Oxyto-
cin mRNA expression is reduced during fasting and this reduction
can be reversed by i.p. injection of leptin (19); hence, we propose
that the actions of leptin may involve an up-regulation of oxytocin
mRNA expression that contributes to a long-term enhancement of
oxytocin secretion in response to afferent stimuli. However, these
signalling pathways that are activated by leptin appear to suppress
rather than potentiate the expression of Fos protein, indicating that
this transcription factor is not involved in leptin-induced up-regula-
tion of oxytocin expression.
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